BerandaGIFLF • OTCMKTS
add
Grifols SA Class A
Tutup sebelumnya
$8,50
Rentang tahun
$8,40 - $11,39
Kapitalisasi pasar
5,97Â M USD
Volume Rata-Rata
107,00
Rasio P/E
-
Hasil dividen
-
Bursa utama
BME
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(EUR) | Des 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 1,98Â M | 11,66% |
Biaya operasional | 353,12Â jt | 20,32% |
Laba bersih | 68,97Â jt | 76,86% |
Margin laba bersih | 3,49 | 58,64% |
Penghasilan per saham | — | — |
EBITDA | 495,68Â jt | -11,49% |
Tarif pajak efektif | 60,20% | — |
Neraca
Total aset
Total liabilitas
(EUR) | Des 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 1,00Â M | 55,40% |
Total aset | 21,41Â M | 1,97% |
Total liabilitas | 12,80Â M | -5,05% |
Total ekuitas | 8,61 M | — |
Saham yang beredar | 680,41 jt | — |
Harga terhadap nilai buku | 0,98 | — |
Tingkat pengembalian aset | 5,08% | — |
Tingkat pengembalian modal | 5,79% | — |
Arus Kas
Perubahan kas bersih
(EUR) | Des 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | 68,97Â jt | 76,86% |
Kas dari operasi | 514,62Â jt | 208,54% |
Kas dari investasi | -178,31Â jt | -28,31% |
Kas dari pembiayaan | -27,16Â jt | -185,08% |
Perubahan kas bersih | 334,84Â jt | 658,87% |
Arus kas bebas | 162,44Â jt | 123,56% |
Tentang
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
CEO
Didirikan
18 Nov 1940
Situs
Karyawan
23.833